MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas

Ovarian cancer is a silent disease with a poor prognosis that urgently requires new therapeutic strategies. In low-grade ovarian tumours, mutations in the MAP3K BRAF gene constitutively activate the downstream kinase MEK. Here we demonstrate that an additional MAP3K, MAP3K8 (TPL-2/COT), accumulates...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruosso, Tina, Garnier, Camille, Abelanet, Sophie, Kieffer, Yann, Lemesre, Vincent, Bellanger, Dorine, Bieche, Ivan, Marangoni, Elisabetta, Sastre-Garau, Xavier, Mieulet, Virginie, Mechta-Grigoriou, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633961/
https://www.ncbi.nlm.nih.gov/pubmed/26456302
http://dx.doi.org/10.1038/ncomms9583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633961/
https://www.ncbi.nlm.nih.gov/pubmed/26456302
http://dx.doi.org/10.1038/ncomms9583

Ejemplares similares